SCHEMBL23575321

SCHEMBL23575321

COc1ccc(Cn2ncc3c(-c4cc(OC)c(CN(C)C(=O)OC(C)(C)C)c(OC)c4)cn(C)c(=O)c32)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD9 Q9H8M2 8/20 0.45
BRD7 Q9NPI1 8/20 0.45
TAF1 P21675 1/20 0.45
TGFBR1 P36897 1/20 0.45
BRPF1 P55201 1/20 0.45
ACVR1 Q04771 1/20 0.45
BPTF Q12830 1/20 0.45
TAF1L Q8IZX4 1/20 0.45
CREBBP Q92793 1/20 0.45
CECR2 Q9BXF3 1/20 0.45
BAZ2B Q9UIF8 1/20 0.45
ATAD2B Q9ULI0 1/20 0.45
BRD4 O60885 7/20 0.44
BRD2 P25440 3/20 0.44
PKM P14618 1/20 0.38
PKLR P30613 1/20 0.38
HTR2C P28335 1/20 0.36
SLC6A4 P31645 1/20 0.36
PDE1A P54750 3/20 0.36
PDE1B Q01064 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23575605 0.90 BRD9 (0.48) BRD9BRD7TAF1TGFBR1BRPF1
SCHEMBL23575671 0.89 BRD9 (0.44) BRD9BRD7TAF1TGFBR1BRPF1
SCHEMBL23575596 0.85 BRD9 (0.49) BRD9BRD7TAF1TGFBR1BRPF1
SCHEMBL23575703 0.85 BRD9 (0.47) BRD9BRD7TAF1TGFBR1BRPF1
SCHEMBL23590080 0.85 BRD4 (0.39) BRD9BRD7TAF1TGFBR1BRPF1
SCHEMBL23783293 0.83 ADORA2A (0.41) BRD9BRD4PKMPKLRTP53
SCHEMBL23575848 0.81 PKM (0.41) BRD9BRD7TAF1TGFBR1BRPF1
SCHEMBL23798558 0.81 BRD4 (0.43) BRD9BRD7TAF1TGFBR1BRPF1
SCHEMBL30207476 0.80 ADORA2A (0.40) BRD9TP53
SCHEMBL23575665 0.80 BRD4 (0.42) BRD9BRD7TAF1TGFBR1BRPF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3846800-A1 COMPOUNDS FOR THE DEGRADATION OF BRD9 OR MTH1 C4 Therapeutics, Inc. (US) 2021-07-14 EP disclosed
US-20210198256-A1 COMPOUNDS FOR THE DEGRADATION OF BRD9 OR MTH1 C4 THERAPEUTICS, INC. (US) 2021-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210198256-A1 COMPOUNDS FOR THE DEGRADATION OF BRD9 OR MTH1 RBBP9, MTHFD1, BRWD1 BRD9 5/4885BRD7 32/4885TAF1 1363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.